Toboroz
A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer
NCT07524855· 1. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
NCT07195916· 1. fázis· Incyte Corporation· Forrás
Toboroz
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT07111520· 1/2. fázis· BioNTech SE· Forrás
Toboroz
A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors
NCT07147348· 1/2. fázis· BioNTech SE· Forrás
Toboroz
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
NCT07070232· 1/2. fázis· BioNTech SE· Forrás
Fut, nem toboroz
A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer
NCT06830850· 1. fázis· Atridia Pty Ltd.· Forrás
Toboroz
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
NCT06340568· 3. fázis· BioNTech SE· Forrás
Toboroz
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
NCT06827236· 1/2. fázis· BioNTech SE· Forrás
Toboroz
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
NCT06801834· 3. fázis· Gilead Sciences· Forrás
Toboroz
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
NCT06750185· 1/2. fázis· BioNTech SE· Forrás
Toboroz
A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors
NCT06533332· 1. fázis· EtiraRx Australia Pty Ltd· Forrás
Contact: Kelly Mead
Fut, nem toboroz
M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)
NCT06421935· 1. fázis· EMD Serono Research & Development Institute, Inc.· Forrás
Toboroz
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
NCT06400472· 1. fázis· Eli Lilly and Company· Forrás
Contact: Meena Okera (principal investigator)
Fut, nem toboroz
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
NCT06225596· 2. fázis· BicycleTx Limited· Forrás
Fut, nem toboroz
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
NCT06065748· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer
NCT05909397· 3. fázis· Pfizer· Forrás
Toboroz
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
NCT05633654· 3. fázis· Gilead Sciences· Forrás
Fut, nem toboroz
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
NCT05388669· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
NCT05142189· 1. fázis· BioNTech SE· Forrás
Fut, nem toboroz
THIO Sequenced With Cemiplimab in Advanced NSCLC
NCT05208944· 2. fázis· Maia Biotechnology· Forrás
Fut, nem toboroz
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
NCT05307705· 1. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
NCT05132582· 3. fázis· Seagen, a wholly owned subsidiary of Pfizer· Forrás
Fut, nem toboroz
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
NCT04956640· 1/2. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
NCT04534205· 2/3. fázis· BioNTech SE· Forrás
Fut, nem toboroz
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
NCT04140526· 1/2. fázis· OncoC4, Inc.· Forrás
Fut, nem toboroz
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
NCT04188548· 1. fázis· Eli Lilly and Company· Forrás